Advanced search
Publication Cover
Bioengineered Volume 10, 2019 - Issue 1
Submit an article Journal homepage
1,726
Views
9
CrossRef citations to date
0
Altmetric
Research Paper

Clinical importance of S100A9 in osteosarcoma development and as a diagnostic marker and therapeutic target

Yongliang Liua Department of Trauma Orthopedics, Linyi Central Hospital, Yishui, Shandong, China
,
Gongzeng Luoa Department of Trauma Orthopedics, Linyi Central Hospital, Yishui, Shandong, China
&
Dongyong Heb Department of Internal Medcine, The Affiliated Hospital of Qingdao University, Qingdao, Shangdong, ChinaCorrespondence[email protected]
Pages 133-141 | Received 05 Feb 2019, Accepted 11 Apr 2019, Published online: 06 May 2019

References

  • Osborne TS, Khanna C. A review of the association between osteosarcoma metastasis and protein translation. J Comp Pathol. 2012;146:132–142.
  • Hattinger CM, Pasello M, Ferrari S, et al. Emerging drugs for high-grade osteosarcoma. Expert Opin Emerg Drugs. 2010;15:615–634.
  • Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program. Cancer. 2009;115:1531–1543.
  • Isakoff MS, Bielack SS, Meltzer P, et al. Osteosarcoma: current treatment and a collaborative pathway to success. J Clin Oncol. 2015;33:3029–3035.
  • Marenholz I, Heizmann CW, Fritz G. S100 proteins in mouse and man: from evolution to function and pathology. Biochem Biophys Res Commun. 2014;322:1111–1122.
  • Salama I, Malone PS, Mihaimeed F, et al. A review of the S100 proteins in cancer. Eur J Surg Oncol. 2008;34:357–364.
  • Hibino T, Sakaguchi M, Miyamoto S, et al. S100A9 is a novel ligand of EMMPRIN that promotes melanoma metastasis. Cancer Res. 2013;73:172–183.
  • Chen S, Zhao H, Deng J, et al. Comparative proteomics of glioma stem cells and differentiated tumor cells identifies S100A9 as a potential therapeutic target. J Cell Biochem. 2013;114:2795–2808.
  • Cheng S, Zhang X, Huang N, et al. Down-regulation of S100A9 inhibits osteosarcoma cell growth through inactivating MAPK and NF-κB signaling pathways. BMC Cancer. 2016;16:253.
  • Okugawa Y, Toiyama Y, Hur K, et al. Metastasis-associated long non-coding RNA drives gastric cancer development and promotes peritoneal metastasis. Carcinogenesis. 2014;35:2731–2739.
  • Huang H, Huang Q, Tang T, et al. Clinical significance of calcium-binding protein S100A8 and S100A9expression in non-small cell lung cancer. Thorac Cancer. 2018;9:800–804.
  • Gunaldi M, Okuturlar Y, Gedikbasi A, et al. Diagnostic importance of S100A9 and S100A12 in breast cancer. Biomed Pharmacother. 2015;76:52–56.
  • Arai K, Takano S, Teratani T, et al. S100A8 and S100A9 overexpression is associated with poor pathological parameters in invasive ductal carcinoma of the breast. Curr Cancer Drug Targets. 2008;8:243–252.
  • Fan B, Zhang LH, Jia YN, et al. Presence of S100A9-positive inflammatory cells in cancer tissues correlates with an early stage cancer and a better prognosis in patients with gastric cancer. BMC Cancer. 2012;12:316.
  • Kim HJ, Kang HJ, Lee H, et al. Identification of S100A8 and S100A9 as serological markers for colorectal cancer. J Proteome Res. 2009;8:1368–1379.
  • Khammanivong A, Sorenson BS, Ross KF, et al. Involvement of calprotectin (S100A8/A9) in molecular pathways associated with HNSCC. Oncotarget. 2016;7:14029–14047.
  • Cross SS, Hamdy FC, Deloulme JC, et al. Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all overexpressed in common cancers. Histopathology. 2005;46:256–269.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.